184 related articles for article (PubMed ID: 33019424)
41. Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Morgan TR; Ghany MG; Kim HY; Snow KK; Shiffman ML; De Santo JL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Dienstag JL; Morishima C; Lindsay KL; Lok AS;
Hepatology; 2010 Sep; 52(3):833-44. PubMed ID: 20564351
[TBL] [Abstract][Full Text] [Related]
42. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
43. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
Kunimoto H; Ikeda K; Sorin Y; Fujiyama S; Kawamura Y; Kobayashi M; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2016; 90(3):167-75. PubMed ID: 26901157
[TBL] [Abstract][Full Text] [Related]
44. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
45. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
Lee HW; Chon YE; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Jung KS; Park YN; Han KH
Gut Liver; 2016 May; 10(3):429-36. PubMed ID: 26347515
[TBL] [Abstract][Full Text] [Related]
46. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
Miki D; Akita T; Kurisu A; Kawaoka T; Nakajima T; Hige S; Karino Y; Toyoda H; Kumada T; Tsuge M; Hiramatsu A; Imamura M; Aikata H; Hayes CN; Honda K; Seike M; Akuta N; Kobayashi M; Kumada H; Tanaka J; Chayama K
J Gastroenterol; 2020 Dec; 55(12):1162-1170. PubMed ID: 33057914
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
48. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
[TBL] [Abstract][Full Text] [Related]
49. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
50. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
51. Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study.
Watanabe M; Yokomori H; Kitahara G; Uehara K; Koyama S; Minamino T; Otsuka T; Kaneko T; Tahara K; Kida M
Intern Med; 2022 Oct; 61(20):3017-3028. PubMed ID: 35945005
[TBL] [Abstract][Full Text] [Related]
52. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years.
Lee HJ; Yeon JE; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Kim JH; Seo YS; Yim HJ; Byun KS
Intervirology; 2015; 58(1):14-21. PubMed ID: 25592614
[TBL] [Abstract][Full Text] [Related]
53. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Seo K; Kim SK; Kim SR; Ohtani A; Kobayashi M; Kato A; Morimoto E; Saijo Y; Kim KI; Imoto S; Kim CW; Yano Y; Kudo M; Hayashi Y
Dig Dis; 2017; 35(6):541-547. PubMed ID: 29040986
[TBL] [Abstract][Full Text] [Related]
54. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
[TBL] [Abstract][Full Text] [Related]
55. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan.
Chi CT; Chen CY; Su CW; Chen PY; Chu CJ; Lan KH; Lee IC; Hou MC; Huang YH
J Microbiol Immunol Infect; 2021 Jun; 54(3):385-395. PubMed ID: 31771822
[TBL] [Abstract][Full Text] [Related]
56. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Liu TW; Tsai PC; Huang CI; Tsai YS; Wang SC; Ko YM; Lin CC; Chen KY; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
J Formos Med Assoc; 2018 Jan; 117(1):54-62. PubMed ID: 28389143
[TBL] [Abstract][Full Text] [Related]
57. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
[TBL] [Abstract][Full Text] [Related]
58. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
Harada N; Hiramatsu N; Oze T; Yamada R; Kurokawa M; Miyazaki M; Yakushijin T; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Gastroenterol; 2013 Apr; 48(4):535-43. PubMed ID: 22976932
[TBL] [Abstract][Full Text] [Related]
59. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
60. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]